Animal models of neurological disease

Advances in Experimental Medicine and Biology

Volumn 671, Issue , 2010, Pages 23-40

  Shah, Amol ^b   Garzon Muvdi, Tomas ^b   Mahajan, Rohit ^b   Duenas, Vincent J ^b   Quinones Hinojosa, Alfredo ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; HUNTINGTIN; LEVODOPA; METHAMPHETAMINE; OXIDOPAMINE; PARAQUAT; RESERPINE; ROTENONE; TAU PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; NEUROTOXIN; UNCOUPLING PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMNESIA; AMYLOID PLAQUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CAG REPEAT; COSMID VECTOR; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; HISTOPATHOLOGY; HUNTINGTON CHOREA; LEWY BODY; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR DISORDER; SYMPTOMATOLOGY; SYNAPTIC TRANSMISSION; ANIMAL; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC AGENTS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; HUMANS; METHAMPHETAMINE; NERVOUS SYSTEM DISEASES; NEUROTOXINS; OXIDOPAMINE; RESERPINE; ROTENONE; UNCOUPLING AGENTS;

EID: 77952970868     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-5819-8_3     Document Type: Article

References (137)

1. Schmid A, DiDonato C. Animal models of spinal muscular atrophy. J Child Neurol 2007; 22(8):1004-12. (Pubitemid 47308315)
2. Cenci M, Whishaw I, Schallert T. Animal models of neurological deficits: How relevant is the rat? Nat Rev Neurosci 2002; 3(7):574-9. (Pubitemid 135706667)
3. DeLong M. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13(7):281-5. (Pubitemid 20193459)
4. Betarbet R, Sherer T, Greenamyre J. Animal models of Parkinson's disease. Bioessays 2002; 24(4):308-18. (Pubitemid 34305686)
5. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2(5):325-34.
6. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180(4596):1200.
7. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966; 18(2):925-64.
8. McMillen B. CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. TIPS 1983(4):429-32.
9. Fibiger HC, Mogeer EG. Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. Eur J Pharmacol 1971; 16(2):176-80.
10. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research.Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50(2-3):275-331. (Pubitemid 26412599)
11. Annett LE, Rogers DC, Hernandez TD et al. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 1992; 115(Pt 3):825-56.
12. Ungerstedt U. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome. Pharmacol Ther B 1976; 2(1):37-40.
13. Hattori N, Sato S. Animal models of Parkinson's disease: Similarities and differences between the disease and models. Neuropathology 2007; 27(5):479-83. (Pubitemid 47459722)
14. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993; 61(4):1191-206. (Pubitemid 23285075)
15. Chan P, DeLanney LE, Irwin I et al. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991; 57(1):348-51.
16. Bloem BR, Irwin I, Buruma OJ et al. The MPTP model: Versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 1990; 97(2-3):273-93. (Pubitemid 20231246)
17. Burns RS, Chiueh CC, Markey SP et al. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proc Natl Acad Sci USA 1983; 80(14):4546-50. (Pubitemid 13077876)
18. Beal M, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc Natl Acad Sci USA 2001; 98(1):3-4. (Pubitemid 32095849)
19. Wichmann T, Bergman H, Starr PA et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates.Exp Brain Res 1999; 125(4):397-409. (Pubitemid 29178674)
20. Wichmann T, Kliem MA, DeLong MR. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp Neurol 2001; 167(2):410-24. (Pubitemid 32150899)
21. Bergman H, Wichmann T, Karmon B et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72(2):507-20. (Pubitemid 24273560)
22. Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991; 547(1):152-61.
23. Bronstein J, DeSalles A, DeLong M. Stereotactic pallidotomy in the treatment of Parkinson disease: An expert opinion. Arch Neurol 1999; 56(9):1064-9. (Pubitemid 29426792)
24. Beal M, Matthews R, Tieleman A et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl- 1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998; 783(1):109-14. (Pubitemid 28131427)
25. Forno L, Langston J, DeLanney L et al. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 1988; 448(1):150-7.
26. Gorell J, Johnson C, Rybicki B et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living. Neurology 1998; 50(5):1346-50. (Pubitemid 28240350)
27. Seidler A, Hellenbrand W, Robra B et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: A case-control study in Germany. Neurology 1996; 46(5):1275-84. (Pubitemid 26159286)
28. Hattori N, Sato S. Animal models of Parkinson's disease: Similarities and differences between the disease and models. Neuropathology 2007; 27(5):479-83. (Pubitemid 47459722)
29. Polymeropoulos M. Genetics of Parkinson's disease. Ann N Y Acad Sci 2000; 920:28-32. (Pubitemid 32056548)
30. Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18(2):106-8.
31. Lücking C, Abbas N, Dürr A et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's disease and the French Parkinson's disease Genetics Study Group. Lancet 1998; 352(9137):1355-6.
32. Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25(3):302-5. (Pubitemid 30437317)
33. Masliah E, Rockenstein E, Veinbergs I et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000; 287(5456):1265-9. (Pubitemid 30112148)
34. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404(6776):394-8. (Pubitemid 30164341)
35. van der Putten H, Wiederhold KH, Probst A et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000; 20(16):6021-9. (Pubitemid 30658395)
36. Feany M, Bender W. A Drosophila model of Parkinson's disease. Nature 2000; 404(6776):394-8. (Pubitemid 30164341)
37. Traystman R. Animal models of focal and global cerebral ischemia. ILAR J 2003; 44(2):85-95. (Pubitemid 36410962)
38. Durukan A, Tatlisumak T. Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87(1):179-97. (Pubitemid 46860315)
39. Garcia J. Experimental ischemic stroke: A review. Stroke 1984; 15(1):5-14. (Pubitemid 14182387)
40. Hossmann K. Experimental models for the investigation of brain ischemia. Cardiovasc Res 1998; 39(1):106-20. (Pubitemid 28322383)
41. Purdy PD, Devous MD Sr, Batjer HH et al. Microfibrillar collagen model of canine cerebral infarction.Stroke 1989; 20(10):1361-7. (Pubitemid 19254552)
42. Lauer KK, Shen H, Stein EA et al. Focal cerebral ischemia in rats produced by intracarotid embolization with viscous silicone. Neurol Res 2002; 24(2):181-90. (Pubitemid 34169264)
43. Dietrich W, Watson B, Busto R et al. Photochemically induced cerebral infarction. I. Early microvascular alterations. Acta Neuropathol 1987; 72(4):315-25. (Pubitemid 17024303)
44. Abe K, Yoshida S, Watson B et al. Alpha-tocopherol and ubiquinones in rat brain subjected to decapitation ischemia. Brain Res 1983; 273(1):166-9. (Pubitemid 13034226)
45. Ikeda M, Yoshida S, Busto R et al. Polyphosphoinositides as a probable source of brain free fatty acids accumulated at the onset of ischemia. J Neurochem 1986; 47(1):123-32. (Pubitemid 16069180)
46. Yoshida S, Busto R, Watson B et al. Postischemic cerebral lipid peroxidation in vitro: Modification by dietary vitamin E. J Neurochem 1985; 44(5):1593-601. (Pubitemid 15058803)
47. Siemkowicz E, Gjedde A. Post-ischemic coma in rat: Effect of different preischemic blood glucose levels on cerebral metabolic recovery after ischemia. Acta Physiol Scand 1980; 110(3):225-32. (Pubitemid 11193206)
48. Kabat H, Dennis C, AB B. Recovery of function following arrest of the brain circulation. Am J Physiol 1941(132):737-47.
49. Grenell R. Central nervous system resistance: I. The effects of temporary arrest of cerebral circulation for periods of two to ten minutes. J Neuropathol Exp Neurol 1946; 5:131-54.
50. Traystman RJ. Animal models of focal and global cerebral ischemia. ILAR J 2003; 44(2):85-95. (Pubitemid 36410962)
51. Scheller M, Grafe M, Zornow M et al. Effects of ischemia duration on neurological outcome, CA1 histopathology and nonmatching to sample learning in monkeys. Stroke 1992; 23(10):1471-6; discussion 7-8.
52. Berkowitz ID, Gervais H, Schleien CL et al. Epinephrine dosage effects on cerebral and myocardial blood flow in an infant swine model of cardiopulmonary resuscitation. Anesthesiology 1991; 75(6):1041-50.
53. Dean JM, Koehler RC, Schleien CL et al. Age-related changes in chest geometry during cardiopulmonary resuscitation. J Appl Physiol 1987; 62(6):2212-9. (Pubitemid 17093430)
54. Michael JR, Guerci AD, Koehler RC et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69(4):822-35. (Pubitemid 14125664)
55. Kofler J, Hattori K, Sawada M et al. Histopathological and behavioral characterization of a novel model of cardiac arrest and cardiopulmonary resuscitation in mice. J Neurosci Methods 2004; 136(1):33-44. (Pubitemid 38569869)
56. Kofler J, Otsuka T, Zhang Z et al. Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. J Cereb Blood Flow Metab 2006; 26(1):135-41. (Pubitemid 41818077)
57. Pulsinelli W, Brierley J. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979; 10(3):267-72. (Pubitemid 9141527)
58. Pulsinelli W, Levy D, Duffy T. Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia. Ann Neurol 1982; 11(5):499-502.
59. Smith M, Bendek G, Dahlgren N et al. Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. Acta Neurol Scand 1984; 69(6):385-401. (Pubitemid 14080982)
60. Levine S, Sohn D. Cerebral ischemia in infant and adult gerbils. Relation to incomplete circle of Willis.Arch Pathol 1969; 87(3):315-7.
61. Crockard A, Iannotti F, Hunstock A et al. Cerebral blood flow and edema following carotid occlusion in the gerbil. Stroke 1980; 11(5):494-8. (Pubitemid 10009782)
62. Osburne R, Halsey JJ. Cerebral blood flow. A predictor of recovery from ischemia in the gerbil. Arch Neurol 1975; 32(7):457-61.
63. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18(4):202-9. (Pubitemid 34273741)
64. Walker FO. Huntington's disease. Lancet 2007; 369(9557):218-28. (Pubitemid 46107685)
65. Duyao MP, Auerbach AB, Ryan A et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995; 269(5222):407-10.
66. Nasir J, Floresco SB, O'Kusky JR et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81(5):811-23.
67. Zeitlin S, Liu JP, Chapman DL et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11(2):155-63.
68. Walling HW, Baldassare JJ, Westfall TC. Molecular aspects of Huntington's disease. J Neurosci Res 1998; 54(3):301-8. (Pubitemid 28493940)
69. Rubinsztein D. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18(4):202-9. (Pubitemid 34273741)
70. Rigamonti D, Bauer J, De-Fraja C et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20(10):3705-13. (Pubitemid 30266233)
71. Rigamonti D, Sipione S, Goffredo D et al. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 2001; 276(18):14545-8.
72. Ho L, Brown R, Maxwell M et al. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 2001; 38(7):450-2. (Pubitemid 32661206)
73. Davies SW, Turmaine M, Cozens BA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3):537-48. (Pubitemid 27347243)
74. Davies S, Turmaine M, Cozens B et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3):537-48. (Pubitemid 27347243)
75. Becher M, Kotzuk J, Sharp A et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998; 4(6):387-97. (Pubitemid 28201657)
76. Wheeler V, White J, Gutekunst C et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000; 9(4):503-13. (Pubitemid 30154008)
77. Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: The human illness and transgenic models. Science 1998; 282(5391):1079-83. (Pubitemid 28516230)
78. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101(1):57-66.
79. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000; 287(5459):1837-40. (Pubitemid 30143971)
80. Fernandez-Funez P, Nino-Rosales M, de Gouyon B et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000; 408(6808):101-6.
81. Marsh J, Walker H, Theisen H et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9(1):13-25. (Pubitemid 30145284)
82. Warrick J, Chan H, Gray-Board G et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23(4):425-8.
83. Parker JA, Connolly JB, Wellington C et al. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci USA 2001; 98(23):13318-23. (Pubitemid 33051360)
84. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34(7):939-44. (Pubitemid 14076461)
85. Morrison J, Hof P. Life and death of neurons in the aging brain. Science 1997; 278(5337):412-9. (Pubitemid 27454417)
86. Wong PC, Cai H, Borchelt DR et al. Genetically engineered mouse models of neurodegenerative diseases.Nat Neurosci 2002; 5(7):633-9. (Pubitemid 34742978)
87. Feany M, Dickson D. Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Ann Neurol 1996; 40(2):139-48. (Pubitemid 26274548)
88. Lee V, Balin B, Otvos LJ et al. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251(4994):675-8. (Pubitemid 21916893)
89. Grundke-Iqbal I, Iqbal K, Quinlan M et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261(13):6084-9. (Pubitemid 17207447)
90. Goedert M, Spillantini M, Cairns N et al. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 1992; 8(1):159-68.
91. Goedert M, Jakes R, Spillantini M et al. Assembly of microtubule- associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996; 383(6600):550-3. (Pubitemid 26346185)
92. Delacourte A, Sergeant N, Wattez A et al. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998; 43(2):193-204. (Pubitemid 28110121)
93. Dickson D. Neurodegenerative diseases with cytoskeletal pathology: A biochemical classification. Ann Neurol 1997; 42(4):541-4. (Pubitemid 27439015)
94. Götz J, Streffer J, David D et al. Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatry 2004; 9(7):664-83. (Pubitemid 38932172)
95. Glenner G, Wong C. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120(3):885-90. (Pubitemid 14104991)
96. Masters C, Simms G, Weinman N et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82(12):4245-9. (Pubitemid 15053619)
97. Mann D, Iwatsubo T, Cairns N et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Abeta42(43). Ann Neurol 1996; 40(2):149-56.
98. Mann D, Iwatsubo T, Nochlin D et al. Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: The Volga German families. Ann Neurol 1997(1):52-7. (Pubitemid 27057092)
99. Lansbury PJ. Structural neurology: Are seeds at the root of neuronal degeneration? Neuron 1997; 19(6):1151-4.
100. Jarrett J, Lansbury PJ. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73(6):1055-8. (Pubitemid 23180480)
101. Mattson M. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives.Physiol Rev 1997; 77(4):1081-132. (Pubitemid 27459580)
102. Yankner B. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996; 16(5):921-32. (Pubitemid 26171198)
103. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21:479-505. (Pubitemid 28150671)
104. Rockenstein E, McConlogue L, Tan H et al. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease.J Biol Chem 1995; 270(47):28257-67.
105. Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373(6514):523-7.
106. Chen G, Chen K, Knox J et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408(6815):975-9. (Pubitemid 32101643)
107. Andra K, Abramowski D, Duke M et al. Expression of APP in transgenic mice: A comparison of neuron-specific promoters. Neurobiol Aging 1996; 17(2):183-90. (Pubitemid 26167631)
108. Borchelt D, Ratovitski T, van Lare J et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19(4):939-45. (Pubitemid 27471397)
109. Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 1996; 274(5284):99-102. (Pubitemid 26332733)
110. Rockenstein E, Crews L, Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 2007; 59(11):1093-102. (Pubitemid 47615209)
111. Borchelt D, Thinakaran G, Eckman C et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17(5):1005-13. (Pubitemid 26424026)
112. Boncristiano S, Calhoun M, Kelly P et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 2002; 22(8):3234-43. (Pubitemid 35379210)
113. Takeuchi A, Irizarry M, Duff K et al. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 2000; 157(1):331-9. (Pubitemid 30641749)
114. Irizarry M, McNamara M, Fedorchak K et al. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997; 56(9):965-73. (Pubitemid 27386126)
115. Irizarry M, Soriano F, McNamara M et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.J Neurosci 1997; 17(18):7053-9. (Pubitemid 27427884)
116. Calhoun M, Wiederhold K, Abramowski D et al. Neuron loss in APP transgenic mice. Nature 1998; 395(6704):755-6. (Pubitemid 28485431)
117. Andrä K, Abramowski D, Duke M et al. Expression of APP in transgenic mice: A comparison of neuron-specific promoters. Neurobiol Aging 1996; 17(2):183-90. (Pubitemid 26167631)
118. Mucke L, Masliah E, Yu G et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 2000; 20(11):4050-8. (Pubitemid 30365675)
119. Gotz J, Probst A, Spillantini MG et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995; 14(7):1304-13.
120. Ishihara T, Zhang B, Higuchi M et al. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol 2001; 158(2):555-62. (Pubitemid 32158616)
121. Lewis J, Dickson D, Lin W et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293(5534):1487-91. (Pubitemid 32801551)
122. Lewis J, McGowan E, Rockwood J et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25(4):402-5. (Pubitemid 32983430)
123. Götz J, Chen F, Barmettler R et al. Tau filament formation in transgenic mice expressing P301L tau.J Biol Chem 2001; 276(1):529-34. (Pubitemid 32050347)
124. Götz J, Tolnay M, Barmettler R et al. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci 2001; 13(11):2131-40. (Pubitemid 32578799)
125. Tanemura K, Akagi T, Murayama M et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 2001; 8(6):1036-45. (Pubitemid 34017097)
126. Tatebayashi Y, Miyasaka T, Chui D et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci USA 2002; 99(21):13896-901. (Pubitemid 35215477)
127. Allen B, Ingram E, Takao M et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22(21):9340-51. (Pubitemid 35356177)
128. Higuchi M, Ishihara T, Zhang B et al. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 2002; 35(3):433-46. (Pubitemid 34879944)
129. Oddo S, Caccamo A, Kitazawa M et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24(8):1063-70. (Pubitemid 37487883)
130. Boutajangout A, Authelet M, Blanchard V et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.Neurobiol Dis 2004; 15(1):47-60. (Pubitemid 38134380)
131. Lu P, Wulf G, Zhou X et al. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999; 399(6738):784-8. (Pubitemid 29293174)
132. Lu K, Liou Y, Vincent I. Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer's disease. Bioessays 2003; 25(2):174-81. (Pubitemid 36222389)
133. Liou Y, Sun A, Ryo A et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003; 424(6948):556-61. (Pubitemid 36975777)
134. Ishihara T, Hong M, Zhang B et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24(3):751-62.
135. Spittaels K, Van den Haute C, Van Dorpe J et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999; 155(6):2153-65.
136. Probst A, Götz J, Wiederhold K et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 2000; 99(5):469-81. (Pubitemid 30201307)
137. Wong PC, Cai H, Borchelt DR et al. Genetically engineered models relevant to neurodegenerative disorders: Their value for understanding disease mechanisms and designing/testing experimental therapeutics.J Mol Neurosci 2001; 17(2):233-57. (Pubitemid 33063527)